title: [Comparison of clinical efficacy of trental various routes administration in hypoxic states of eye posterior segment].
abstract: Ninety-four patients with acute and chronic diseases of the posterior segment of the eye (optic nerve atrophy, central chorioretinal dystrophy, ischemic neuropathy, circulatory disorders in the central retinal artery and its branches) were examined. Clinical efficacy of various routes of administration of trental (intravenous, parabulbar, and by subtenon implantation of a collagen infusion system--SICIS) was evaluated in patients with ischemic states of the posterior segment of the eye. The most pronounced improvement of visual acuity was observed after administration through collagen infusion system. In acute and chronic hypoxic diseases of the posterior segment of the eye the time course of the rheographic coefficient was virtually the same after intravenous and parabulbar administration, while after SICIS the rheographic coefficient was significantly higher. Therefore, SICIS is the most effective method for trental administration in patients with acute and chronic diseases of the posterior segment of the eye; parabulbar administration ranks second in efficiency. This recommends SICIS as the most effective method for trental administration.
authors.forename: T O
authors.initials: TO
authors.lastname: Eliseeva
authors.forename: A V
authors.initials: AV
authors.lastname: Svirin
authors.forename: N A
authors.initials: NA
authors.lastname: Bishele
authors.forename: M V
authors.initials: MV
authors.lastname: Brodskaia
mesh_terms: D001783:Blood Flow Velocity / Q000187:drug effects; D015862:Choroid Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004333:Drug Administration Routes; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy* / Q000503:physiopathology; D018917:Optic Neuropathy, Ischemic / Q000188:drug therapy* / Q000503:physiopathology; D010431:Pentoxifylline / Q000008:administration & dosage* / Q000627:therapeutic use; D015356:Retinal Artery Occlusion / Q000188:drug therapy* / Q000503:physiopathology; D012162:Retinal Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents; D010431:Pentoxifylline